The Analysis Study of The Association of Metformin and Pancreatic Cancer in Diabetic Patients: A Comprehensive Systematic Review

Abstract

Background: Pancreatic cancer is ranked 14th globally in terms of cancer incidence and 7th in cancer mortality. The connection between diabetes and pancreatic cancer is intricate and debated. Recent research indicates that metformin might reduce the incidence of pancreatic cancer in patients with T2DM. Methods: Following PRISMA 2020 guidelines, this systematic review focused exclusively on full-text articles published in English between 2014 and 2024. Result: The study conducted a comprehensive review of over 100 publications sourced from reputable databases, including ScienceDirect, SagePub, and PubMed. Following an initial screening, eight publications were identified as warranting more in-depth analysis. Consequently, a thorough review of these selected studies was performed to ensure a detailed and rigorous evaluation. Conclusion: Metformin has the potential to lower the risk of pancreatic cancer in individuals with diabetes. Future prospective studies are necessary to validate this perspective.